Exane Asset Management Invests $585,000 in Edwards Lifesciences Co. (NYSE:EW)

Exane Asset Management acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,629 shares of the medical research company’s stock, valued at approximately $585,000. Edwards Lifesciences comprises 0.3% of Exane Asset Management’s investment portfolio, making the stock its 19th largest position.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Czech National Bank raised its position in shares of Edwards Lifesciences by 6.9% in the third quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock valued at $8,098,000 after purchasing an additional 7,883 shares during the period. GAMMA Investing LLC raised its holdings in Edwards Lifesciences by 21.6% during the 3rd quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 730 shares during the period. Alpha Financial Partners LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $693,000. Boston Common Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 4.0% in the third quarter. Boston Common Asset Management LLC now owns 207,924 shares of the medical research company’s stock worth $13,721,000 after acquiring an additional 7,973 shares during the period. Finally, West Coast Financial LLC grew its position in shares of Edwards Lifesciences by 0.6% in the third quarter. West Coast Financial LLC now owns 143,213 shares of the medical research company’s stock valued at $9,451,000 after purchasing an additional 874 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock worth $547,430 in the last ninety days. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.38 on Friday. The firm has a market cap of $41.51 billion, a price-to-earnings ratio of 10.16, a PEG ratio of 3.72 and a beta of 1.11. The company has a 50-day simple moving average of $72.47 and a two-hundred day simple moving average of $69.55. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research note on Thursday, January 16th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Finally, Piper Sandler decreased their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.